Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. reports developments in remote patient monitoring, cardiac diagnostics and chronic condition management. The company operates a Technology-as-a-Service model built around remote cardiac monitoring solutions for medical and consumer markets, including Bioheart wearable monitoring and cloud-based workflow tools.
Recurring news covers financial results, revenue trends, margin performance, operating efficiency and business update calls. Company updates also include adoption of remote cardiac monitoring solutions, collaborations for consumer wearable ECG data, and the use of automation and AI-enabled cloud infrastructure in cardiac monitoring workflows.
Biotricity (NASDAQ:BTCY) has launched Biocare Cardiac, a comprehensive cardiac disease management solution, following successful pilot programs in Oklahoma and Kentucky. This innovative platform integrates diagnostics, remote patient monitoring, and telemedicine, designed for cardiologists and their patients. Over 2,000 cardiologists are expected to utilize this tool, which provides actionable data to enhance patient care. Monthly reports and alerts enable physicians to intervene promptly based on real-time patient data, potentially improving health outcomes.
Biotricity (NASDAQ:BTCY) announced that Waqaas Al-Siddiq, the Founder and CEO, will speak at the American Medical Device Summit on October 19, 2022, in Chicago. The panel discussion focuses on medical devices in at-home patient care and will take place from 4:20 p.m. to 4:55 p.m. CST. The summit will feature over 50 speakers and 200 attendees, providing insights into trends and innovations in medical devices. Biotricity aims to enhance chronic care management and remote monitoring solutions.
Biotricity Inc. (NASDAQ:BTCY) has announced a significant milestone, surpassing 2 billion heartbeats analyzed for Atrial Fibrillation (AFib), a major cardiac arrhythmia. The company utilizes its Bioflux mobile telemetry device for real-time ECG monitoring, enhanced by proprietary AI algorithms. This achievement is positioned to facilitate better automation, scalable operations, and growth in margins. The global AFib market is projected to reach USD 26 billion by 2027, with Biotricity aiming to leverage its R&D capabilities for a competitive edge in predictive monitoring.
Biotricity Inc. (NASDAQ:BTCY) announced a Phase I study on its innovative AI system, Bioflux-AI, for real-time monitoring of stroke risk in Chronic Kidney Disease (CKD) patients. Sponsored by the NIH, the study aims to address the significantly higher stroke risk in CKD patients, which is 5 to 30 times greater than the general population. The technology combines mobile cardiac telemetry with AI algorithms to improve predictive accuracy, targeting a reduction in mortality rates and healthcare costs associated with CKD treatment. Biotricity aims to enhance personalized care through this initiative.
Biotricity (NASDAQ: BTCY) reported its fiscal 2023 first-quarter financial results on August 15, 2022, revealing a revenue of $2.1 million and a gross profit of $1.2 million, maintaining a gross margin of 60%. The company experienced a net loss of $5 million, or $0.098 per share. CEO Dr. Waqaas Al-Siddiq highlighted the successful rollout of new product lines, including Biotres and Bioheart, following FDA clearance. The expansion aims to enhance the Biotricity ecosystem and target hospital networks.
Biotricity Inc. (BTCY) reported significant growth in its fiscal 2022 results, achieving a 126% increase in annual revenue to $7.7 million. The fourth quarter saw an 81% rise in revenue, totaling $2.15 million, with gross profit margins enhancing to 67%. Despite robust revenue growth, the company recorded a net loss of $30.2 million for FY22. Biotricity launched new products including Biotres and Bioheart, expanding its market to approximately $25 billion. The company holds $12 million in cash and has enhanced its industry profile by being listed on NASDAQ.
Biotricity Inc. (NASDAQ:BTCY) announced its expected inclusion in the Russell Microcap® Index effective June 27, 2022. This membership, determined by market capitalization and style attributes, is significant for the company as Russell indexes are widely utilized by investment managers and institutional investors, with approximately $12 trillion in assets benchmarked against them. The inclusion also means Biotricity will be part of both growth and value style indexes for one year, enhancing its visibility in the financial markets.
Biotricity Inc. (NASDAQ:BTCY) will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The Company’s Founder & CEO, Dr. Waqaas Al-Siddiq, is scheduled to speak on May 24th at 3:30 PM ET at Splash 16. He will discuss the Company’s business developments and future objectives as Biotricity aims to become a comprehensive cardiac diagnostics platform. This hybrid event offers both virtual and in-person participation, emphasizing Biotricity’s commitment to innovation in healthcare.
Biotricity (NASDAQ:BTCY) reported strong strategic initiatives and growth opportunities in its recent shareholder update. The company has expanded its national sales force to cover 27 states, enhancing demonstrations of its cardiac devices. The FDA cleared its Biotres cardiac monitoring device, expanding its total addressable market (TAM) from $1B to $25B. Biotricity achieved a significant 93% YOY revenue growth to $1.93 million in Q3 2021 and raised $12 million in non-dilutive debt financing. As COVID-19 recedes, the company anticipates increased sales opportunities in 2022.
Biotricity (NASDAQ:BTCY) announced pre-order sales of its FDA-cleared wireless wearable device, Biotres, designed for early detection of cardiac arrhythmias. Official commercial sales will launch in April 2022, following strong pre-order demand from physicians and individual users. Biotres, a three-lead device, enhances ECG monitoring efficiency compared to traditional Holter monitors, positioning the company to tap into a $5.7 billion market. Biotricity plans to expand its product line throughout 2022, aiming to increase revenue and customer reach.